Difference between revisions of "Drug index"
Jump to navigation
Jump to search
m (FDA approval - Carfilzomib) |
m (added medications) |
||
| Line 1: | Line 1: | ||
| − | *[[ | + | *[[Antidepressants and other psychiatric medications in cancer care]] |
*[[Antiemesis|Antiemetic support]] | *[[Antiemesis|Antiemetic support]] | ||
| − | |||
| − | |||
*[http://jco.ascopubs.org/content/30/13/1553.long Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline]<ref>Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. [http://jco.ascopubs.org/content/30/13/1553.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/22473167 PubMed]</ref> | *[http://jco.ascopubs.org/content/30/13/1553.long Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline]<ref>Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. [http://jco.ascopubs.org/content/30/13/1553.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/22473167 PubMed]</ref> | ||
*[http://www.theoncologypharmacist.com/sites/theoncologypharmacist.com/files/Chemotherapy%20Administration.pdf Chemotherapy Administration Sequence]<ref>Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. [http://www.theoncologypharmacist.com/sites/theoncologypharmacist.com/files/Chemotherapy%20Administration.pdf link to original article]</ref> - with chemotherapy sequencing chart | *[http://www.theoncologypharmacist.com/sites/theoncologypharmacist.com/files/Chemotherapy%20Administration.pdf Chemotherapy Administration Sequence]<ref>Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. [http://www.theoncologypharmacist.com/sites/theoncologypharmacist.com/files/Chemotherapy%20Administration.pdf link to original article]</ref> - with chemotherapy sequencing chart | ||
| + | *[[Steroid conversions]] | ||
| + | *[[Vesicant & irritant chemotherapy]] | ||
==A== | ==A== | ||
| Line 134: | Line 134: | ||
==G== | ==G== | ||
| + | *[[Galeterone (TOK-001)]] '''in clinical trials''' | ||
*[[Ganetespib (STA-9090)]] '''in clinical trials''' | *[[Ganetespib (STA-9090)]] '''in clinical trials''' | ||
*[[Ganitumab (AMG 479)]] '''in clinical trials''' | *[[Ganitumab (AMG 479)]] '''in clinical trials''' | ||
| Line 298: | Line 299: | ||
*[[Zoledronic acid (Zometa)]] | *[[Zoledronic acid (Zometa)]] | ||
| − | == | + | ==References== |
<references/> | <references/> | ||
Revision as of 03:52, 24 July 2012
- Antidepressants and other psychiatric medications in cancer care
- Antiemetic support
- Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline[1]
- Chemotherapy Administration Sequence[2] - with chemotherapy sequencing chart
- Steroid conversions
- Vesicant & irritant chemotherapy
A
- Abiraterone (Zytiga)
- Afatinib (BIBW 2992) in clinical trials
- Aflibercept (Zaltrap) in clinical trials
- Aldesleukin (Proleukin)
- Alemtuzumab (Campath)
- All-trans retinoic acid (ATRA)
- Altretamine (Hexalen)
- AMG 386 in clinical trials
- Amifostine (Ethyol)
- Aminocaproic acid (Amicar)
- Aminoglutethimide (Cytadren)
- Amsacrine (Amsidine)
- Anagrelide (Agrylin)
- Anastrozole (Arimidex)
- Antithrombin III (human and recombinant)
- Antithymocyte globulin (ATG)
- Argatroban
- Arsenic trioxide (Trisenox)
- Asparaginase (Elspar)
- Asparaginase Erwinia chrysanthemi (Erwinaze) FDA approved 11/18/2011
- Aspirin
- Atovaquone (Mepron)
- Axitinib (Inlyta) FDA approved 1/27/2012
- Azacitidine (Vidaza)
B
- Bacillus Calmette-Guerin (BCG, TheraCys)
- Bendamustine (Treanda)
- Bevacizumab (Avastin)
- Bexarotene (Targretin)
- Bicalutamide (Casodex)
- Bivalirudin (Angiomax)
- BHQ880 (Anti-DKK1 Antibody) in clinical trials
- Bleomycin (Blenoxane)
- Bortezomib (Velcade)
- Brentuximab vedotin (Adcetris) FDA approved 8/19/2011
- Brivanib (BMS-582664) in clinical trials
- Busulfan (Myleran)
- Bosutinib (SKI-606) in clinical trials
C
- Cabazitaxel (Jevtana)
- Cabozantinib (XL184) in clinical trials
- CAL-101 in clinical trials
- Calcium phosphate rinse (Caphosol)
- Capecitabine (Xeloda)
- Carboplatin (Paraplatin)
- Carfilzomib (Kyprolis) FDA approved 7/20/2012
- Carmustine (BiCNU)
- Carmustine wafer, polifeprosan 20 (Gliadel)
- CAT-3888 (BL22) in clinical trials
- Catumaxomab (Removab) in US clinical trials
- Cetuximab (Erbitux)
- Chlorambucil (Leukeran)
- Cisplatin (Platinol)
- Cladribine (Leustatin)
- Clofarabine (Clolar)
- Clopidogrel (Plavix)
- Crizotinib (Xalkori)
- Cyanocobalamin (Vitamin B12)
- Cyclophosphamide (Cytoxan)
- Cyclosporine modified (Neoral)
- Cyclosporine non-modified (Sandimmune)
- Cytarabine (Cytosar)
- Cytarabine liposomal (DepoCyt)
- Cytomegalovirus (CMV) Human Immunoglobulin (Cytogam)
D
- Dabigatran (Pradaxa)
- Dacarbazine (DTIC)
- Dactinomycin (Cosmegen)
- Dalteparin (Fragmin)
- Darbepoetin alfa (Aranesp)
- Dasatinib (Sprycel)
- Daunorubicin (Cerubidine)
- Daunorubicin liposomal (DaunoXome)
- Decitabine (Dacogen)
- Deferasirox (Exjade)
- Deferiprone (Ferriprox) FDA approved 10/14/2011
- Deferoxamine (Desferal)
- Degarelix (Firmagon)
- Denileukin diftitox (Ontak)
- Denosumab (Xgeva)
- Desmopressin (DDAVP)
- Dexamethasone (Decadron)
- Dexrazoxane (Zinecard)
- Docetaxel (Taxotere)
- Doxorubicin (Adriamycin)
- Doxorubicin liposomal (Doxil)
- Dutasteride (Avodart)
E
- Eculizumab (Soliris)
- Elotuzumab (HuLuc63) in clinical trials
- Eltrombopag (Promacta)
- Enoxaparin (Lovenox)
- Entinostat in clinical trials
- Enzalutamide (MDV3100) in clinical trials
- Epirubicin (Ellence)
- Epoetin alfa (Procrit)
- Eribulin (Halaven)
- Erlotinib (Tarceva)
- Estramustine (Emcyt)
- Etoposide (Vepesid)
- Everolimus (Afinitor)
- Exemestane (Aromasin)
F
- Factor VIIa, recombinant (NovoSeven RT)
- Factor VIII, human and recombinant (antihemophilic factor 8)
- Factor IX, human and recombinant (coagulation factor 9)
- Factor IX complex (Profilnine)
- Factor XIII concentrate, human (Corifact)
- Ferric gluconate (Ferrlecit)
- Ferrous sulfate (Feosol)
- Ferumoxytol (Feraheme)
- Filgrastim (Neupogen)
- Finasteride (Proscar)
- Fluorouracil (5-FU)
- Floxuridine (FUDR)
- Fludarabine (Fludara)
- Flutamide (Eulexin)
- Folinic acid (Leucovorin)
- Fondaparinux (Arixtra)
- Fulvestrant (Faslodex)
G
- Galeterone (TOK-001) in clinical trials
- Ganetespib (STA-9090) in clinical trials
- Ganitumab (AMG 479) in clinical trials
- Gefitinib (Iressa)
- Gemcitabine (Gemzar)
- Gemtuzumab ozogamicin (Mylotarg)
- Glucarpidase (Voraxaze) FDA approved 1/17/2012
- Goserelin (Zoladex)
H
- Hematopoetic progenitor cells, cord blood (Hemacord) FDA approved 11/10/2011
- Heparin
- HER2 peptide vaccine (AE37) in clinical trials
- Hydroxyurea (Hydrea)
I
- Ibritumomab tiuxetan (Zevalin)
- Ibrutinib (PCI-32765) in clinical trials
- Idarubicin (Idamycin)
- Ifosfamide (Ifex)
- Imatinib (Gleevec)
- Ipilimumab (Yervoy)
- Interferon alfa-2a (Roferon-A)
- Interferon alfa-2b (Intron-A)
- IPH 2101 (Anti-KIR) in clinical trials
- Irinotecan (Camptosar)
- Iron dextran (INFeD)
- Iron sucrose (Venofer)
- Ixabepilone (Ixempra)
L
- Lapatinib (Tykerb)
- Lenalidomide (Revlimid)
- Lepirudin (Refludan)
- Letrozole (Femara)
- Leuprolide (Lupron)
- Levoleucovorin (Fusilev)
- Lomustine (Ceenu)
M
- Mechlorethamine (Mustargen)
- Melphalan (Alkeran)
- Mercaptopurine (Purinethol)
- Mesna (Mesnex)
- Methotrexate (MTX)
- Methoxsalen (Uvadex)
- Mitomycin (Mutamycin)
- Mitotane (Lysodren)
- Mitoxantrone (Novantrone)
- MLN9708 (MLN2238) in clinical trials
- Motesanib (AMG 706) in clinical trials
- Moxetumomab pasudotox (HA22) in clinical trials
- Mycophenolate mofetil (CellCept)
N
- Nelarabine (Arranon)
- Neratinib (HKI-272) in clinical trials
- Nilotinib (Tasigna)
- Nilutamide (Nilandron)
- NovoTTF-100A device
O
- Obinutuzumab (GA101) in clinical trials
- Octreotide (Sandostatin)
- Odanacatib (MK-0822) in clinical trials
- Ofatumumab (Arzerra)
- Olaparib (AZD-2281) in clinical trials
- Omacetaxine mepesuccinate (Omapro) in clinical trials
- Onartuzumab (MetMAb) in clinical trials
- Oxaliplatin (Eloxatin)
P
- Paclitaxel (Taxol)
- Paclitaxel, nanoparticle albumin-bound (Abraxane)
- Pamidronate (Aredia)
- Panitumumab (Vectibix)
- Panobinostat (LBH589) in clinical trials
- Pazopanib (Votrient)
- Pegaspargase (Oncaspar)
- Pegfilgrastim (Neulasta)
- Peginterferon alfa-2a (Pegasys)
- Peginterferon alfa-2b (PegIntron)
- Pemetrexed (Alimta)
- Pentamidine (Nebupent)
- Pentostatin (Nipent)
- Pertuzumab (Perjeta) FDA approved 6/8/2012
- Phytonadione (Vitamin K)
- Plerixafor (Mozobil)
- Plicamycin (Mithracin)
- Pomalidomide (Actimid) in clinical trials
- Ponatinib (AP24534) in clinical trials
- Porfimer (Photofrin)
- Pralatrexate (Folotyn)
- Prednisone (Sterapred)
- Procarbazine (Matulane)
- Protamine sulfate
R
- Radium-223 (Alpharadin) in clinical trials
- Raloxifene (Evista)
- Ramucirumab (IMC-1121B) in clinical trials
- Regorafenib (BAY 73-4506) in clinical trials
- Reovirus (Reolysin) in clinical trials
- Retaspimycin (IPI-504) in clinical trials
- Ridaforolimus (AP23573) in clinical trials
- Rituximab (Rituxan)
- Rivaroxaban (Xarelto) FDA approved 7/1/2011
- Romidepsin (Istodax)
- Romiplostim (Nplate)
- Ruxolitinib (Jakafi) FDA approved 11/16/2011
S
- Samarium-153 (Quadramet)
- Sargramostim (Leukine)
- Selumetinib (AZD6244) in clinical trials
- Semuloparin (AVE5026) in clinical trials
- Sipuleucel-T (Provenge)
- Sorafenib (Nexavar)
- Streptozocin (Zanosar)
- Sunitinib (Sutent)
T
- Tacrolimus (Prograf)
- Tamoxifen (Nolvadex)
- Temozolomide (Temodar)
- Temsirolimus (Torisel)
- Teniposide (Vumon)
- TH-302 in clinical trials
- Thalidomide (Thalomid)
- Thioguanine (Tabloid)
- Thiotepa (Thioplex)
- Tivantinib (ARQ 197) in clinical trials
- Topotecan (Hycamtin)
- Toremifene (Fareston)
- Tositumomab & I-131 (Bexxar)
- Trabectedin (Yondelis)
- Trastuzumab (Herceptin)
- Trastuzumab emtansine (T-DM1) in clinical trials
- Tretinoin (Vesanoid)
- Trimethoprim/Sulfamethoxazole (Bactrim DS)
- Triptorelin (Trelstar LA)
U
V
- Valrubicin (Valstar)
- Vandetanib (Caprelsa)
- Veltuzumab (hA20) in clinical trials
- Vemurafenib (Zelboraf) FDA approved 8/17/2011
- Vinblastine (Velban)
- Vincristine (Oncovin)
- Vincristine liposomal (Marqibo) in clinical trials
- Vindesine (Eldisine)
- Vinorelbine (Navelbine)
- Vismodegib (Erivedge) FDA approved 1/30/2012
- Von Willebrand Factor and factor VIII complex, human
- Vorinostat (Zolinza)
W
Z
References
- ↑ Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. link to original article PubMed
- ↑ Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. link to original article